Optomed Launch­es Next-Gen­er­a­tion Hand­held Fun­dus Cam­era to Pow­er the Future of Ocu­lomics in Every­day Health­care

Optomed has announced the launch of Optomed Lumo®, a next-gen­er­a­tion hand­held fun­dus cam­era designed to bring reti­nal imag­ing and the emerg­ing sci­ence of ocu­lomics into every­day health­care set­tings.

Ocu­lomics is a grow­ing field focused on using the reti­na to detect signs of sys­temic dis­ease. With Optomed Lumo, the com­pa­ny aims to make this tech­nol­o­gy more acces­si­ble, par­tic­u­lar­ly in pri­ma­ry care, com­mu­ni­ty clin­ics, and non-spe­cial­ist envi­ron­ments. With this launch, Optomed is deliv­er­ing on its vision to enable screen­ing for all by equip­ping pri­ma­ry care clin­ics, com­mu­ni­ty health cen­ters, and non-spe­cial­ist set­tings with the tools to eas­i­ly detect ear­ly signs of sys­temic dis­ease.

Non-mydri­at­ic Optomed Lumo sets a new stan­dard for effi­cien­cy in reti­nal diag­nos­tics with its pro­gram­ma­ble work­flows, intu­itive user guid­ance and seam­less inte­gra­tion into var­i­ous med­ical work­flows. Designed with input from health­care pro­fes­sion­als, this fun­dus cam­era offers intu­itive oper­a­tion with high-qual­i­ty imag­ing and AI-enhanced diag­nos­tic plat­forms, allow­ing for faster deci­sion-mak­ing.

Optomed Lumo is MDR Class IIa CE cer­ti­fied med­ical device. Ini­tial deliv­er­ies are expect­ed to begin in Q3 2025 in select­ed mar­kets, with a broad­er roll­out planned in sub­se­quent quar­ters.

About Optomed

Optomed is a Finnish med­ical tech­nol­o­gy com­pa­ny and a lead­ing man­u­fac­tur­er of hand­held fun­dus cam­eras and screen­ing soft­ware. Optomed com­bines hand­held fun­dus cam­eras with soft­ware and arti­fi­cial intel­li­gence with the aim of trans­form­ing the diag­nos­tic process of var­i­ous dis­eases, such as rapid­ly increas­ing dia­bet­ic retinopa­thy. Optomed has offices in Fin­land, the US, and Chi­na, and the company’s prod­ucts are sold via var­i­ous sales chan­nels in over 60 coun­tries glob­al­ly.

Source: Optomed